CG Oncology, Inc. Common stock
CGONNASDAQHealthcare● Active
$54.40
+$0.68(+1.27%)
Market Cap$4.8B
P/E Ratio—
52W High$75.5
52W Low$23.65
CG Oncology, Inc. Common stock (CGON) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CGON · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($161.00M) | ($88.04M) | ($48.61M) | ($35.44M) | ($12.84M) |
| Depreciation & Amort. | $1.45M | $0.03M | $0.02M | $0.01M | $0.01M |
| Stock-Based Comp. | $26.68M | $11.40M | $1.53M | $0.68M | $1.11M |
| Change in Working Capital | $2.28M | $2.91M | $3.44M | $4.44M | ($1.97M) |
| Net Cash from Operations | ($132.35M) | ($78.71M) | ($45.68M) | ($29.80M) | ($13.65M) |
| Investing Activities | |||||
| Capital Expenditure | ($0.13M) | ($0.23M) | $0.00M | ($0.01M) | ($0.10M) |
| Purchases of Investments | ($1067.86M) | ($1045.94M) | ($517.61M) | ($55.34M) | $0.00M |
| Sales of Investments | $844.14M | $745.41M | $396.42M | $0.00M | $0.00M |
| Net Cash from Investing | ($245.82M) | ($300.76M) | ($121.19M) | ($55.35M) | ($0.10M) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.00M | ($0.36M) | ($16.29M) | $0.00M | $15.20M |
| Net Cash from Financing | $153.59M | $628.28M | $87.00M | $119.69M | $15.45M |
| Free Cash Flow | |||||
| Free Cash Flow | ($132.48M) | ($78.95M) | ($45.68M) | ($29.82M) | ($13.75M) |
| FCF Margin %(computed) | — | — | — | — | -132.76% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more CG Oncology, Inc. Common stock data
About CG Oncology, Inc. Common stock (CGON) Cash Flow Statement
CG Oncology, Inc. Common stock generated operating cash flow of ($0.13B) and free cash flow of ($0.13B) for 2025 — a FCF margin of -3279.21%. Capital expenditure was ($0.00B).
Frequently asked questions
CGON · 4 questionsCG Oncology, Inc. Common stock generated free cash flow of ($0.13B) for 2025, down 67.8% year-over-year.
CGON free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10